| Exclusion Criteria: | 1) Uncontrolled concurrent illness such as unstable angina, myocardial infarction in the preceding month, neutropenic fever, shock, symptomatic decompensate congestive heart failure, or congestive Heart Failure of NYHA III or IV, active internal bleeding.
2) Hypersensitivity to olanzapine, or history of dyskinesia or extrapyramidal syndrome on atypical neuroleptic.
3) Concurrent treatment with any atypical antipsychotic such as clozapine, resperidone, olanzapine, quetiapine, ziprasidone or aribpriprazole
4) History of clozapine-induced agranulocytosis because patients will be at increased risk for neutropenia with Olanzapine.
5) Major surgery within four weeks of study start day.
6) Uncontrolled diabetes mellitus
7) Uncontrolled seizure disorder (any episode in the previous 4 weeks).
8) Pregnant and Nursing women.
9) Patients may not have started an appetite stimulant such as megace or therapeutic dose of steroids (superior or equal to an equivalent of 4 mg dexamethasone/day), or increased the dose of such medication (by more than 50%) in the previous week. |